A detailed history of Jpmorgan Chase & CO transactions in Cerus Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 79,870 shares of CERS stock, worth $124,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,870
Previous 89,177 10.44%
Holding current value
$124,597
Previous $168,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.62 - $2.04 $15,077 - $18,986
-9,307 Reduced 10.44%
79,870 $140,000
Q1 2024

May 10, 2024

SELL
$1.66 - $2.42 $141,244 - $205,910
-85,087 Reduced 48.83%
89,177 $168,000
Q4 2023

Feb 12, 2024

BUY
$1.25 - $2.35 $63,291 - $118,987
50,633 Added 40.95%
174,264 $376,000
Q3 2023

Nov 14, 2023

SELL
$1.5 - $3.07 $25,356 - $51,895
-16,904 Reduced 12.03%
123,631 $200,000
Q2 2023

Aug 11, 2023

BUY
$1.79 - $2.9 $5,915 - $9,584
3,305 Added 2.41%
140,535 $345,000
Q1 2023

May 18, 2023

BUY
$2.65 - $3.81 $350,340 - $503,697
132,204 Added 2630.4%
137,230 $407,000
Q1 2023

May 11, 2023

SELL
$2.65 - $3.81 $317,122 - $455,938
-119,669 Reduced 95.97%
5,026 $14,000
Q4 2022

Feb 13, 2023

SELL
$3.38 - $4.22 $39,336 - $49,112
-11,638 Reduced 8.54%
124,695 $454,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $141,538 - $240,574
41,265 Added 43.41%
136,333 $490,000
Q2 2022

Aug 11, 2022

BUY
$4.41 - $5.69 $59,182 - $76,359
13,420 Added 16.44%
95,068 $503,000
Q1 2022

May 11, 2022

BUY
$4.81 - $6.99 $65,108 - $94,616
13,536 Added 19.87%
81,648 $448,000
Q4 2021

Feb 10, 2022

BUY
$5.97 - $7.93 $18,041 - $23,964
3,022 Added 4.64%
68,112 $464,000
Q3 2021

Nov 12, 2021

BUY
$4.79 - $6.68 $311,781 - $434,801
65,090 New
65,090 $396,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $276M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.